The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (original) (raw)

• Faith, J. J. et al. The long-term stability of the human gut microbiota. Science 341, 1237439 (2013).
  PubMed PubMed Central Google Scholar
• Kuczynski, J. et al. Experimental and analytical tools for studying the human microbiome. Nat. Rev. Genet. 13, 47–58 (2012).
  CAS Google Scholar
• Maurice, C. F., Haiser, H. J. & Turnbaugh, P. J. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 152, 39–50 (2013). This study is the first to develop methods to define the metabolically active set of gut bacteria and demonstrate that xenobiotics shape the structure and physiology of these bacteria.
  CAS PubMed PubMed Central Google Scholar
• Maurice, C. F. & Turnbaugh, P. J. Quantifying the metabolic activities of human-associated microbial communities across multiple ecological scales. FEMS Microbiol. Rev. 37, 830–848 (2013).
  CAS PubMed Google Scholar
• O'Hara, A. M. & Shanahan, F. The gut flora as a forgotten organ. EMBO Rep. 7, 688–693 (2006).
  CAS PubMed PubMed Central Google Scholar
• Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).
  CAS PubMed PubMed Central Google Scholar
• Eckburg, P. B. et al. Diversity of the human intestinal microbial flora. Science 308, 1635–1638 (2005).
  PubMed PubMed Central Google Scholar
• David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563 (2014).
  CAS PubMed Google Scholar
• Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. Nature 486, 222–227 (2012).
  CAS PubMed PubMed Central Google Scholar
• Goodrich, J. K. et al. Human genetics shape the gut microbiome. Cell 159, 789–799 (2014).
  CAS PubMed PubMed Central Google Scholar
• Thaiss, C. A. et al. Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell 159, 514–529 (2014).
  CAS PubMed Google Scholar
• Diaz Heijtz, R. et al. Normal gut microbiota modulates brain development and behavior. Proc. Natl Acad. Sci. USA 108, 3047–3052 (2011).
  PubMed Google Scholar
• Foster, J. A. & McVey Neufeld, K. A. Gut–brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 36, 305–312 (2013).
  CAS PubMed Google Scholar
• Hsiao, E. Y. et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155, 1451–1463 (2013).
  CAS PubMed PubMed Central Google Scholar
• Arthur, J. C. et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338, 120–123 (2012).
  CAS PubMed PubMed Central Google Scholar
• Kostic, A. D. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14, 207–215 (2013).
  CAS PubMed PubMed Central Google Scholar
• Fierer, N. et al. Forensic identification using skin bacterial communities. Proc. Natl Acad. Sci. USA 107, 6477–6481 (2010).
  CAS PubMed PubMed Central Google Scholar
• Franzosa, E. A. et al. Identifying personal microbiomes using metagenomic codes. Proc. Natl Acad. Sci. USA 112, E2930–E2938 (2015).
  CAS PubMed PubMed Central Google Scholar
• Liou, A. P. et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci. Transl. Med. 5, 178ra141 (2013).
  Google Scholar
• Roopchand, D. E. et al. Dietary polyphenols promote growth of the gut bacterium Akkermansia muciniphila and attenuate high-fat diet-induced metabolic syndrome. Diabetes 64, 2847–2858 (2015). This study suggests that the beneficial effects of dietary polyphenols may be mediated by the gut microbiome.
  CAS PubMed PubMed Central Google Scholar
• Fuller, A. T. Is _p_-aminobenzenesulphonamide the active agent in protonsil therapy? Lancet 229, 194–198 (1937).
  Google Scholar
• Colebrook, L., Buttle, G. A. H. & O'Meara, R. A. Q. The mode of action of _p_-aminobenzene sulphonamide and prontosil in hemolytic streptococcal infections. Lancet 228, 1323–1326 (1936).
  Google Scholar
• Radomski, J. L. & Mellinger, T. J. The absorption, fate and excretion in rats of the water-soluble azo dyes, FD&C Red No. 2, FD&C Red No. 4, and FD&C Yellow No. 6. J. Pharmacol. Exp. Ther. 136, 259–266 (1962).
  CAS PubMed Google Scholar
• Klotz, U., Maier, K., Fischer, C. & Heinkel, K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N. Engl. J. Med. 303, 1499–1502 (1980).
  CAS PubMed Google Scholar
• Plosker, G. L. & Croom, K. F. Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs 65, 1825–1849 (2005).
  CAS PubMed Google Scholar
• Rocco, T. P. & Fang, J. C. in Goodman & Gilman's The Pharmacological Basis of Therapeutics (eds Brunton, L. L., Lazo, J. S. & Parker, K. L.) (McGraw-Hill, 2011).
  Google Scholar
• Grundmann, O. The gut microbiome and pre-systemic metabolism: current state and evolving research. J. Drug Metab. Toxicol. 1, 1–7 (2010).
  Google Scholar
• Haiser, H. J. & Turnbaugh, P. J. Developing a metagenomic view of xenobiotic metabolism. Pharmacol. Res. 69, 21–31 (2013).
  CAS PubMed Google Scholar
• Li, H. & Jia, W. Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. Clin. Pharmacol. Ther. 94, 574–581 (2013).
  CAS PubMed Google Scholar
• Nicholson, J. K., Holmes, E. & Wilson, I. D. Gut microorganisms, mammalian metabolism and personalized health care. Nat. Rev. Microbiol. 3, 431–438 (2005).
  CAS PubMed Google Scholar
• Saad, R., Rizkallah, M. R. & Aziz, R. K. Gut pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes. Gut Pathog. 4, 16 (2012).
  CAS PubMed PubMed Central Google Scholar
• Tralau, T., Sowada, J. & Luch, A. Insights on the human microbiome and its xenobiotic metabolism: what is known about its effects on human physiology? Expert Opin. Drug Metab. Toxicol. 11, 411–425 (2015).
  CAS PubMed Google Scholar
• Pond, S. M. & Tozer, T. N. First-pass elimination. Basic concepts and clinical consequences. Clin. Pharmacokinet. 9, 1–25 (1984).
  CAS PubMed Google Scholar
• Backhed, F., Ley, R. E., Sonnenburg, J. L., Peterson, D. A. & Gordon, J. I. Host–bacterial mutualism in the human intestine. Science 307, 1915–1920 (2005).
  PubMed Google Scholar
• Arkhipova, O. V. & Akimenko, V. K. Unsaturated organic acids as terminal electron acceptors for reductase chains of anaerobic bacteria. Microbiology 76, 725–737 (2005).
  Google Scholar
• Novel, G., Didier-Fichet, M. L. & Stoeber, F. Inducibility of β-glucuronidase in wild-type and hexuronate-negative mutants of Escherichia coli K-12. J. Bacteriol. 120, 89–95 (1974).
  CAS PubMed PubMed Central Google Scholar
• Haiser, H. J., Seim, K. L., Balskus, E. P. & Turnbaugh, P. J. Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes 5, 233–238 (2014).
  PubMed PubMed Central Google Scholar
• de Groot, M. J. Designing better drugs: predicting cytochrome P450 metabolism. Drug Discov. Today 11, 601–606 (2006).
  CAS PubMed Google Scholar
• Zanger, U. M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103–141 (2013).
  CAS PubMed Google Scholar
• Bachrach, W. H. Sulfasalazine: I. An historical perspective. Am. J. Gastroenterol. 83, 487–496 (1988).
  CAS PubMed Google Scholar
• Svartz, N. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. Am. J. Gastroenterol. 83, 497–503 (1988).
  CAS PubMed Google Scholar
• Peppercorn, M. A. & Goldman, P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J. Pharmacol. Exp. Ther. 181, 555–562 (1972).
  CAS PubMed Google Scholar
• Chen, H., Wang, R. F. & Cerniglia, C. E. Molecular cloning, overexpression, purification, and characterization of an aerobic FMN-dependent azoreductase from Enterococcus faecalis. Protein Expr. Purif. 34, 302–310 (2004).
  CAS PubMed PubMed Central Google Scholar
• Morrison, J. M., Wright, C. M. & John, G. H. Identification, isolation and characterization of a novel azoreductase from Clostridium perfringens. Anaerobe 18, 229–234 (2012).
  CAS PubMed Google Scholar
• Sousa, T. et al. On the colonic bacterial metabolism of azo-bonded prodrugs of 5-aminosalicylic acid. J. Pharm. Sci. 103, 3171–3175 (2014).
  CAS PubMed Google Scholar
• Delomenie, C. et al. Identification and functional characterization of arylamine _N_-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J. Bacteriol. 183, 3417–3427 (2001).
  CAS PubMed PubMed Central Google Scholar
• Carmody, R. N. & Turnbaugh, P. J. Host–microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J. Clin. Invest. 124, 4173–4181 (2014).
  CAS PubMed PubMed Central Google Scholar
• Wells, P. G. et al. Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab. Dispos. 32, 281–290 (2004).
  CAS PubMed Google Scholar
• Wiseman, L. R. & Markham, A. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 52, 606–623 (1996).
  CAS PubMed Google Scholar
• Stein, A., Voigt, W. & Jordan, K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther. Adv. Med. Oncol. 2, 51–63 (2010).
  CAS PubMed PubMed Central Google Scholar
• Mani, S., Boelsterli, U. A. & Redinbo, M. R. Understanding and modulating mammalian–microbial communication for improved human health. Annu. Rev. Pharmacol. Toxicol. 54, 559–580 (2014).
  CAS PubMed Google Scholar
• Rothenberg, M. L. et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J. Clin. Oncol. 14, 1128–1135 (1996).
  CAS PubMed Google Scholar
• Higuchi, K. et al. Present status and strategy of NSAIDs-induced small bowel injury. J. Gastroenterol. 44, 879–888 (2009).
  PubMed Google Scholar
• Saitta, K. S. et al. Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. Xenobiotica 44, 28–35 (2014). This study demonstrates that the toxicity associated with NSAIDs can be alleviated by inhibiting bacterial enzyme activity with small-molecule inhibitors.
  CAS PubMed Google Scholar
• Beaud, D., Tailliez, P. & Anba-Mondoloni, J. Genetic characterization of the β-glucuronidase enzyme from a human intestinal bacterium, Ruminococcus gnavus. Microbiology 151, 2323–2330 (2005).
  CAS PubMed Google Scholar
• Dabek, M., McCrae, S. I., Stevens, V. J., Duncan, S. H. & Louis, P. Distribution of β-glucosidase and β-glucuronidase activity and of β-glucuronidase gene gus in human colonic bacteria. FEMS Microbiol. Ecol. 66, 487–495 (2008).
  CAS PubMed Google Scholar
• Flores, R. et al. Association of fecal microbial diversity and taxonomy with selected enzymatic functions. PLoS ONE 7, e39745 (2012).
  CAS PubMed PubMed Central Google Scholar
• Roy, D. & Ward, P. Rapid detection of Bifidobacterium dentium by enzymatic hydrolysis of β-glucuronide substrates. J. Food Protect. 55, 291–295 (1992).
  CAS Google Scholar
• Russell, W. M. & Klaenhammer, T. R. Identification and cloning of gusA, encoding a new β-glucuronidase from Lactobacillus gasseri ADH. Appl. Environ. Microbiol. 67, 1253–1261 (2001).
  CAS PubMed PubMed Central Google Scholar
• Wallace, B. D. et al. Structure and inhibition of microbiome β-glucuronidases essential to the alleviation of cancer drug toxicity. Chem. Biol. 22, 1238–1249 (2015).
  CAS PubMed PubMed Central Google Scholar
• Lindenbaum, J. et al. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N. Engl. J. Med. 305, 789–794 (1981).
  CAS PubMed Google Scholar
• Matzuk, M. M., Shlomchik, M. & Shaw, L. M. Making digoxin therapeutic drug monitoring more effective. Ther. Drug Monit. 13, 215–219 (1991).
  CAS PubMed Google Scholar
• Peters, U., Falk, L. C. & Kalman, S. M. Digoxin metabolism in patients. Arch. Intern. Med. 138, 1074–1076 (1978).
  CAS PubMed Google Scholar
• Saha, J. R., Butler, V. P., Neu, H. C. & Lindenbaum, J. Digoxin-inactivating bacteria: identification in human gut flora. Science 220, 325–327 (1983).
  CAS PubMed Google Scholar
• Mathan, V. I., Wiederman, J., Dobkin, J. F. & Lindenbaum, J. Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora. Gut 30, 971–977 (1989).
  CAS PubMed PubMed Central Google Scholar
• Rowland, I. R. Factors affecting metabolic activity of the intestinal microflora. Drug Metab. Rev. 19, 243–261 (1988).
  CAS PubMed Google Scholar
• Haiser, H. J. et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341, 295–298 (2013). This study is the first to show that the bacterial inactivation of drugs can be predicted with a genetic marker and can be prevented using dietary intervention.
  CAS PubMed PubMed Central Google Scholar
• Hooper, L. V. et al. Molecular analysis of commensal host–microbial relationships in the intestine. Science 291, 881–884 (2001).
  CAS PubMed Google Scholar
• Bjorkholm, B. et al. Intestinal microbiota regulate xenobiotic metabolism in the liver. PLoS ONE 4, e6958 (2009).
  PubMed PubMed Central Google Scholar
• Lundin, A. et al. Gut flora, Toll-like receptors and nuclear receptors: a tripartite communication that tunes innate immunity in large intestine. Cell. Microbiol. 10, 1093–1103 (2008).
  CAS PubMed Google Scholar
• Claus, S. P. et al. Colonization-induced host–gut microbial metabolic interaction. mBio 2, e00271-10 (2011).
  PubMed PubMed Central Google Scholar
• Selwyn, F. P., Cui, J. Y. & Klaassen, C. D. RNA-seq quantification of hepatic drug processing genes in germ-free mice. Drug Metab. Dispos. 43, 1572–1580 (2015).
  CAS PubMed PubMed Central Google Scholar
• Claus, S. P. et al. Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. Mol. Syst. Biol. 4, 219 (2008).
  PubMed PubMed Central Google Scholar
• Wikoff, W. R. et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl Acad. Sci. USA 106, 3698–3703 (2009). This study demonstrates that the microbiome has a substantial role in the signature and abundance of circulating metabolites in mammalian blood.
  CAS PubMed PubMed Central Google Scholar
• Hodgman, M. J. & Garrard, A. R. A review of acetaminophen poisoning. Crit. Care Clin. 28, 499–516 (2012).
  PubMed Google Scholar
• Court, M. H. et al. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J. Pharmacol. Exp. Ther. 299, 998–1006 (2001).
  CAS PubMed Google Scholar
• Harrill, A. H. et al. Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res. 19, 1507–1515 (2009).
  CAS PubMed PubMed Central Google Scholar
• Clayton, T. A., Baker, D., Lindon, J. C., Everett, J. R. & Nicholson, J. K. Pharmacometabonomic identification of a significant host–microbiome metabolic interaction affecting human drug metabolism. Proc. Natl Acad. Sci. USA 106, 14728–14733 (2009). This study is the first to demonstrate the potential of using levels of microbial metabolites as predictive biomarkers for drug metabolism.
  CAS PubMed PubMed Central Google Scholar
• Bone, E., Tamm, A. & Hill, M. The production of urinary phenols by gut bacteria and their possible role in the causation of large bowel cancer. Am. J. Clin. Nutr. 29, 1448–1454 (1976).
  CAS PubMed Google Scholar
• Selmer, T. & Andrei, P. I. _p_-hydroxyphenylacetate decarboxylase from Clostridium difficile. A novel glycyl radical enzyme catalysing the formation of _p_-cresol. Eur. J. Biochem. 268, 1363–1372 (2001).
  CAS PubMed Google Scholar
• Gamage, N. et al. Human sulfotransferases and their role in chemical metabolism. Toxicol. Sci. 90, 5–22 (2006).
  CAS PubMed Google Scholar
• Mangravite, L. M., Thorn, C. F. & Krauss, R. M. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenom. J. 6, 360–374 (2006).
  CAS Google Scholar
• Kaddurah-Daouk, R. et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS ONE 6, e25482 (2011).
  CAS PubMed PubMed Central Google Scholar
• Mitchell, J. B. et al. A low molecular weight antioxidant decreases weight and lowers tumor incidence. Free Radic. Biol. Med. 34, 93–102 (2003).
  CAS PubMed Google Scholar
• Li, F. et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat. Commun. 4, 2384 (2013).
  PubMed Google Scholar
• Jiang, J. et al. Diversity of bile salt hydrolase activities in different lactobacilli toward human bile salts. Ann. Microbiol. 60, 81–88 (2010).
  CAS Google Scholar
• de Wit, N. J. et al. The role of the small intestine in the development of dietary fat-induced obesity and insulin resistance in C57BL/6J mice. BMC Med. Genom. 1, 14 (2008).
  Google Scholar
• Sayin, S. I. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-β-muricholic acid, a naturally occurring FXR antagonist. Cell. Metab. 17, 225–235 (2013).
  CAS PubMed Google Scholar
• Tsuda, T. Regulation of adipocyte function by anthocyanins; possibility of preventing the metabolic syndrome. J. Agr. Food Chem. 56, 642–646 (2008).
  CAS Google Scholar
• Quesada, H. et al. Grape seed proanthocyanidins correct dyslipidemia associated with a high-fat diet in rats and repress genes controlling lipogenesis and VLDL assembling in liver. Int. J. Obes. (Lond.) 33, 1007–1012 (2009).
  CAS Google Scholar
• Tsuda, T., Horio, F., Uchida, K., Aoki, H. & Osawa, T. Dietary cyanidin 3-_O_-β-d-glucoside-rich purple corn color prevents obesity and ameliorates hyperglycemia in mice. J. Nutr. 133, 2125–2130 (2003).
  CAS PubMed Google Scholar
• Baiges, I., Palmfeldt, J., Blade, C., Gregersen, N. & Arola, L. Lipogenesis is decreased by grape seed proanthocyanidins according to liver proteomics of rats fed a high fat diet. Mol. Cell. Proteom. 9, 1499–1513 (2010).
  CAS Google Scholar
• Cefalu, W. T. et al. Botanicals and the metabolic syndrome. Am. J. Clin. Nutr. 87, 481S–487S (2008).
  CAS PubMed Google Scholar
• Felgines, C. et al. Radiolabelled cyanidin 3-_O_-glucoside is poorly absorbed in the mouse. Br. J. Nutr. 103, 1738–1745 (2010).
  CAS PubMed Google Scholar
• Abia, R. & Fry, S. C. Degradation and metabolism of 14C-labelled proanthocyanidins from carob (Ceratonia siliqua) pods in the gastrointestinal tract of the rat. J. Sci. Food Agr. 81, 1156–1165 (2001).
  CAS Google Scholar
• Anhe, F. F. et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut 64, 872–883 (2015).
  CAS PubMed Google Scholar
• Everard, A. et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl Acad. Sci. USA 110, 9066–9071 (2013).
  CAS PubMed PubMed Central Google Scholar
• Santacruz, A. et al. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. Br. J. Nutr. 104, 83–92 (2010).
  CAS PubMed Google Scholar
• Zhang, H. et al. Human gut microbiota in obesity and after gastric bypass. Proc. Natl Acad. Sci. USA 106, 2365–2370 (2009).
  CAS PubMed PubMed Central Google Scholar
• Everard, A. et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 60, 2775–2786 (2011).
  CAS PubMed PubMed Central Google Scholar
• Shin, N. R. et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63, 727–735 (2014). This study suggests that the anti-diabetic drug metformin may act, in part, by altering the gut microbiome.
  CAS PubMed Google Scholar
• Axling, U. et al. Green tea powder and Lactobacillus plantarum affect gut microbiota, lipid metabolism and inflammation in high-fat fed C57BL/6J mice. Nutr. Metab. (Lond.) 9, 105 (2012).
  CAS Google Scholar
• Kemperman, R. A. et al. Impact of polyphenols from black tea and red wine/grape juice on a gut model microbiome. Food Res. Int. 53, 659–669 (2013).
  CAS Google Scholar
• Haslam, E. Natural polyphenols (vegetable tannins) as drugs: possible modes of action. J. Nat. Prod. 59, 205–215 (1996).
  CAS PubMed Google Scholar
• Nunez-Sanchez, M. A. et al. Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients. Mol. Nutr. Food. Res. 58, 1199–1211 (2014).
  CAS PubMed Google Scholar
• Garcia-Munoz, C. & Vaillant, F. Metabolic fate of ellagitannins: implications for health, and research perspectives for innovative functional foods. Crit. Rev. Food Sci. Nutr. 54, 1584–1598 (2014).
  CAS PubMed Google Scholar
• Tomas-Barberan, F. A., Garcia-Villalba, R., Gonzalez-Sarrias, A., Selma, M. V. & Espin, J. C. Ellagic acid metabolism by human gut microbiota: consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status. J. Agr. Food Chem. 62, 6535–6538 (2014).
  CAS Google Scholar
• Garcia-Villalba, R., Beltran, D., Espin, J. C., Selma, M. V. & Tomas-Barberan, F. A. Time course production of urolithins from ellagic acid by human gut microbiota. J. Agr. Food Chem. 61, 8797–8806 (2013).
  CAS Google Scholar
• Selma, M. V., Beltran, D., Garcia-Villalba, R., Espin, J. C. & Tomas-Barberan, F. A. Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species. Food Funct. 5, 1779–1784 (2014).
  CAS PubMed Google Scholar
• Adlercreutz, H. Lignans and human health. Crit. Rev. Clin. Lab Sci. 44, 483–525 (2007).
  CAS PubMed Google Scholar
• Lampe, J. W. Is equol the key to the efficacy of soy foods? Am. J. Clin. Nutr. 89, 1664S–1667S (2009).
  CAS PubMed PubMed Central Google Scholar
• Patisaul, H. B. & Jefferson, W. The pros and cons of phytoestrogens. Front. Neuroendocrinol. 31, 400–419 (2010).
  CAS PubMed PubMed Central Google Scholar
• Setchell, K. D. & Clerici, C. Equol: history, chemistry, and formation. J. Nutr. 140, 1355S–1362S (2010).
  CAS PubMed PubMed Central Google Scholar
• Wu, A. H., Yu, M. C., Tseng, C. C. & Pike, M. C. Epidemiology of soy exposures and breast cancer risk. Br. J. Cancer 98, 9–14 (2008).
  CAS PubMed PubMed Central Google Scholar
• Setchell, K. D., Brown, N. M. & Lydeking-Olsen, E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J. Nutr. 132, 3577–3584 (2002).
  CAS PubMed Google Scholar
• Duncan, A. M., Merz-Demlow, B. E., Xu, X., Phipps, W. R. & Kurzer, M. S. Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 9, 581–586 (2000).
  CAS PubMed Google Scholar
• Virk-Baker, M. K., Barnes, S., Krontiras, H. & Nagy, T. R. S-(−)equol producing status not associated with breast cancer risk among low isoflavone-consuming US postmenopausal women undergoing a physician-recommended breast biopsy. Nutr. Res. 34, 116–125 (2014).
  CAS PubMed Google Scholar
• Mazur, W. & Adlercreutz, H. Natural and anthropogenic environmental oestrogens: the scientific basis for risk assessment. Pure Appl. Chem. 70, 1759–1776 (1998).
  CAS Google Scholar
• Penalvo, J. L., Haajanen, K. M., Botting, N. & Adlercreutz, H. Quantification of lignans in food using isotope dilution gas chromatography/mass spectrometry. J. Agr. Food Chem. 53, 9342–9347 (2005).
  CAS Google Scholar
• Clavel, T., Borrmann, D., Braune, A., Dore, J. & Blaut, M. Occurrence and activity of human intestinal bacteria involved in the conversion of dietary lignans. Anaerobe 12, 140–147 (2006).
  CAS PubMed Google Scholar
• Mabrok, H. B. et al. Lignan transformation by gut bacteria lowers tumor burden in a gnotobiotic rat model of breast cancer. Carcinogenesis 33, 203–208 (2012). This study determines that the microbial production of bioactive metabolites from dietary sources mediates anticancer effects for the host.
  CAS PubMed Google Scholar
• Kaderlik, K. R. et al. Glucuronidation of _N_-hydroxy heterocyclic amines by human and rat liver microsomes. Carcinogenesis 15, 1695–1701 (1994).
  CAS PubMed Google Scholar
• Hirayama, K. et al. Effects of human intestinal flora on mutagenicity of and DNA adduct formation from food and environmental mutagens. Carcinogenesis 21, 2105–2111 (2000).
  CAS PubMed Google Scholar
• Kassie, F. et al. Intestinal microflora plays a crucial role in the genotoxicity of the cooked food mutagen 2-amino-3-methylimidazo[4,5-_f_]quinoline. Carcinogenesis 22, 1721–1725 (2001).
  CAS PubMed Google Scholar
• Humblot, C. et al. β-glucuronidase in human intestinal microbiota is necessary for the colonic genotoxicity of the food-borne carcinogen 2-amino-3-methylimidazo[4,5-_f_]quinoline in rats. Carcinogenesis 28, 2419–2425 (2007). This study shows that microbial glucuronidation activity in the gut contributes to the carcinogenic effect of heterocyclic amines from charred meat.
  CAS PubMed Google Scholar
• Craciun, S. & Balskus, E. P. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc. Natl Acad. Sci. USA 109, 21307–21312 (2012).
  CAS PubMed PubMed Central Google Scholar
• Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63 (2011). This study demonstrates that the metabolism of dietary lipids by gut bacteria contributes to heart disease.
  CAS PubMed PubMed Central Google Scholar
• Tang, W. H. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 368, 1575–1584 (2013).
  CAS PubMed PubMed Central Google Scholar
• Koeth, R. A. et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19, 576–585 (2013).
  CAS PubMed PubMed Central Google Scholar
• Drasar, B. S., Renwick, A. G. & Williams, R. T. The role of the gut flora in the metabolism of cyclamate. Biochem. J. 129, 881–890 (1972).
  CAS PubMed PubMed Central Google Scholar
• Legator, M. S., Palmer, K. A., Green, S. & Petersen, K. W. Cytogenetic studies in rats of cyclohexylamine, a metabolite of cyclamate. Science 165, 1139–1140 (1969).
  CAS PubMed Google Scholar
• Tamura, M., Hoshi, C. & Hori, S. Xylitol affects the intestinal microbiota and metabolism of daidzein in adult male mice. Int. J. Mol. Sci. 14, 23993–24007 (2013).
  PubMed PubMed Central Google Scholar
• Suez, J. et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature 514, 181–186 (2014).
  CAS PubMed Google Scholar
• Brown, R. J., de Banate, M. A. & Rother, K. I. Artificial sweeteners: a systematic review of metabolic effects in youth. Int. J. Pediatr. Obes. 5, 305–312 (2010).
  PubMed PubMed Central Google Scholar
• Chassaing, B. et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 519, 92–96 (2015). This research shows that dietary supplements can disrupt mucus–bacterial interactions, promoting gut inflammation.
  CAS PubMed PubMed Central Google Scholar
• Hau, A. K., Kwan, T. H. & Li, P. K. Melamine toxicity and the kidney. J. Am. Soc. Nephrol. 20, 245–250 (2009).
  CAS PubMed Google Scholar
• Ingelfinger, J. R. Melamine and the global implications of food contamination. N. Engl. J. Med. 359, 2745–2748 (2008).
  CAS PubMed Google Scholar
• Zheng, X. et al. Melamine-induced renal toxicity is mediated by the gut microbiota. Sci. Transl. Med. 5, 172ra122 (2013). This study attributes the toxicity of dietary contaminants to gut microbial metabolism.
  Google Scholar
• Shelton, D. R., Karns, J. S., McCarty, G. W. & Durham, D. R. Metabolism of melamine by Klebsiella terragena. Appl. Environ. Microbiol. 63, 2832–2835 (1997).
  CAS PubMed PubMed Central Google Scholar
• Jutzi, K., Cook, A. M. & Hutter, R. The degradative pathway of the _s_-triazine melamine. The steps to ring cleavage. Biochem. J. 208, 679–684 (1982).
  CAS PubMed PubMed Central Google Scholar
• Podschun, R. Isolation of Klebsiella terrigena from human feces: biochemical reactions, capsule types, and antibiotic sensitivity. Zentralbl. Bakteriol. 275, 73–78 (1991).
  CAS PubMed Google Scholar
• Sonnenburg, J. L. & Fischbach, M. A. Community health care: therapeutic opportunities in the human microbiome. Sci. Transl. Med. 3, 78ps12 (2011).
  PubMed PubMed Central Google Scholar
• Ahmad, S. et al. A high throughput assay for discovery of bacterial β-glucuronidase inhibitors. Curr. Chem. Genom. 5, 13–20 (2011).
  CAS Google Scholar
• Ahmad, S., Hughes, M. A., Yeh, L. A. & Scott, J. E. Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors. J. Biomol. Screen 17, 957–965 (2012).
  PubMed PubMed Central Google Scholar
• Roberts, A. B., Wallace, B. D., Venkatesh, M. K., Mani, S. & Redinbo, M. R. Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity. Mol. Pharmacol. 84, 208–217 (2013).
  CAS PubMed PubMed Central Google Scholar
• Wallace, B. D. et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831–835 (2010). This is the first study to show that the toxicity associated with the microbial metabolism of cancer drugs in the gut can be mitigated using bacterial enzyme-specific small-molecule inhibitors.
  CAS PubMed PubMed Central Google Scholar
• LoGuidice, A., Wallace, B. D., Bendel, L., Redinbo, M. R. & Boelsterli, U. A. Pharmacologic targeting of bacterial β-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. J. Pharmacol. Exp. Ther. 341, 447–454 (2012).
  CAS PubMed PubMed Central Google Scholar
• Carmody, R. N. et al. Diet dominates host genotype in shaping the murine gut microbiota. Cell Host Microbe 17, 72–84 (2015).
  CAS PubMed Google Scholar
• Lee, J. R. et al. Gut microbiota and tacrolimus dosing in kidney transplantation. PLoS ONE 10, e0122399 (2015).
  PubMed PubMed Central Google Scholar
• Hooper, L. V., Littman, D. R. & Macpherson, A. J. Interactions between the microbiota and the immune system. Science 336, 1268–1273 (2012).
  CAS PubMed PubMed Central Google Scholar
• Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971–976 (2013).
  CAS PubMed PubMed Central Google Scholar
• Viaud, S. et al. Cyclophosphamide induces differentiation of TH17 cells in cancer patients. Cancer Res. 71, 661–665 (2011).
  CAS PubMed Google Scholar
• Iida, N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967–970 (2013).
  CAS PubMed PubMed Central Google Scholar
• Ozben, T. Oxidative stress and apoptosis: impact on cancer therapy. J. Pharm. Sci. 96, 2181–2196 (2007).
  CAS PubMed Google Scholar
• Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084–1089 (2015).
  CAS PubMed PubMed Central Google Scholar
• Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079–1084 (2015).
  CAS PubMed PubMed Central Google Scholar
• Garrett, W. S. et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 131, 33–45 (2007).
  CAS PubMed PubMed Central Google Scholar
• Neurath, M. F. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 7, 6–19 (2014).
  CAS PubMed Google Scholar
• Rooks, M. G. et al. Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission. ISME J. 8, 1403–1417 (2014).
  CAS PubMed PubMed Central Google Scholar
• Donia, M. S. et al. A systematic analysis of biosynthetic gene clusters in the human microbiome reveals a common family of antibiotics. Cell 158, 1402–1414 (2014). This study reveals the potential of the human microbiome as a rich source of bioactive natural products, including antibiotics.
  CAS PubMed PubMed Central Google Scholar
• Rupnik, M., Wilcox, M. H. & Gerding, D. N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7, 526–536 (2009).
  CAS PubMed Google Scholar
• Buffie, C. G. et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205–208 (2015).
  CAS PubMed Google Scholar
• Sorg, J. A. & Sonenshein, A. L. Inhibiting the initiation of Clostridium difficile spore germination using analogs of chenodeoxycholic acid, a bile acid. J. Bacteriol. 192, 4983–4990 (2010).
  CAS PubMed PubMed Central Google Scholar
• Wilson, K. H. Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J. Clin. Microbiol. 18, 1017–1019 (1983).
  CAS PubMed PubMed Central Google Scholar